


**CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (PREVIOUSLY AMENDED) A composition comprising a compound elected from the group consisting of reduced isoalpa acids, dihydro-isolalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids; and a non-aspirin, non-steroidal anti-inflammatory compound.

2. (CANCELED)

3. (PREVIOUSLY AMENDED) The composition of claim 1, wherein said compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids has the formula:




wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

wherein R'' is selected from the group consisting of CH(CH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, and CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>;

and wherein R, T, X, and Z are independently selected from the group consisting of H, F, Cl, Br, I, and  $\pi$  orbital, with the proviso that if one of R, T, X, or Z is a  $\pi$  orbital, then the adjacent R, T, X, or Z is also a  $\pi$  orbital, thereby forming a double bond.

4. (PREVIOUSLY AMENDED) The composition of claim 1, wherein the composition comprises a reduced isoalpa acid compound of Genus A having the formula:




(Genus A),

wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR,  
 wherein R is alkyl;

and wherein R'' is selected from the group consisting of CH(CH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, and  
 CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>.

5. (PREVIOUSLY AMENDED) The composition of claim 1, wherein the comprises a tetra-  
 hydroisoalpa acid or a hexa-hydroisoalpa acid compound of Genus B having the  
 formula:



(Genus B),


wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR,  
 wherein R is alkyl;

and wherein R'' is selected from the group consisting of CH(CH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, and  
 CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>.

6. (PREVIOUSLY AMENDED) The composition of claim 1, wherein said compound selected from  
 the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-  
 hydroisoalpa acids, and hexa-hydroisoalpa acids comprises a member selected from  
 the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-  
 adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-  
 adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-  
 adhumulone.

7. (PREVIOUSLY AMENDED) The composition of claim 1, wherein the composition comprises about 0.5 to 10,000 mg of said compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids.
8. (PREVIOUSLY AMENDED) The composition of claim 7, wherein the composition comprises about 50 to 7,500 mg of the compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids.
9. (PREVIOUSLY AMENDED) The composition of claim 1, wherein the composition comprises about 0.001 to 10 weight percent of the compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids.
10. (PREVIOUSLY AMENDED) The composition of claim 9, wherein the composition comprises about 0.1 to 1 weight percent of the compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids.
11. (ORIGINAL) The composition of claim 1, wherein the non-aspirin, nonsteroidal anti-inflammatory compound is selected from the group consisting of salicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetanilide, acetaminophen, phenacetin, mefenamic acid, sodium meclofenamate, tolmetin, ketorolac, diclofenac, ibuprofen, naproxen, sodium daproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, meloxicam, tenoxicam, ampiroxicam, droxicam, pivoxicam, phenylbutazone, oxyphenbutazone, anitpyrine, aminopyrine, dipyrone, celecoxib, rofecoxib, nabumetone, apazone, nimensulide, indomethacin, sulindac, and etodolac.
12. (ORIGINAL) The composition of claim 1, wherein the non-aspirin, nonsteroidal anti-inflammatory compound is selected from the group consisting of salicylic acid, methyl salicylate, ibuprofen, naproxen, sodium daproxen, fenoprofen, ketoprofen, flurbiprofen, and oxaprozin.

13. (ORIGINAL) The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.
14. (ORIGINAL) The composition of claim 1, wherein the composition is formulated for administration orally, topically, parenterally, or rectally.
15. (PREVIOUSLY AMENDED) A composition comprising a reduced isoalpa acid and a non-steroidal anti-inflammatory compound.
16. (PREVIOUSLY AMENDED) The composition of claim 15, wherein the reduced isoalpa acid is selected from dihydro-isohumulone, dihydro-isocohumulone, and dihydro-adhumulone.
17. (PREVIOUSLY AMENDED) A method of producing an analgesic and an anti-ulcerogenic-effect in a mammal, comprising administering to the mammal an amount of a compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids sufficient to produce an analgesic and anti-ulcerogenic effect and a nonsteroidal anti-inflammatory compound, whereby administration of said compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids reduces gastric toxicity associated with said non-steroidal anti-inflammatory compound.
18. (PREVIOUSLY AMENDED) The method of claim 17, wherein the compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids comprises of a member of supragenus having the formula:




(Supragenus),

wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR,  
wherein R is alkyl;

wherein R'' is selected from the group consisting of  $\text{CH}(\text{CH}_3)_2$ ,  $\text{CH}_2\text{CH}(\text{CH}_3)_2$ , and  $\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ ;

and wherein R, T, X, and Z are independently selected from the group consisting of H, F, Cl, Br, I, and  $\pi$  orbital, with the proviso that if one of R, T, X, or Z is a  $\pi$  orbital, then the adjacent R, T, X, or Z is also a  $\pi$  orbital, thereby forming a double bond.


19. (PREVIOUSLY AMENDED) The method of claim 17, wherein said compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids comprises a member of Genus A having the formula:



wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

and wherein R'' is selected from the group consisting of  $\text{CH}(\text{CH}_3)_2$ ,  $\text{CH}_2\text{CH}(\text{CH}_3)_2$ , and  $\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ .

20. (PREVIOUSLY AMENDED) The method of claim 17, wherein the compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids comprises a member of Genus B having the formula:



wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR,  
wherein R is alkyl;

and wherein R'' is selected from the group consisting of CH(CH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, and  
CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>.

21. (PREVIOUSLY AMENDED) The method of claim 17, wherein said compound selected from the group consisting of reduced isoalpha acids, dihydro-isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids comprises a member selected from the group consisting of humulone, cohumulone, adhumulone, isohumulone, isocohumulone, isoadhumulone, dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone.
22. (PREVIOUSLY AMENDED) The method of claim 17, wherein the composition comprises about 0.5 to 10000 mg of said compound selected from the group consisting of reduced isoalpha acids, dihydro-isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.
23. (PREVIOUSLY AMENDED) The method of claim 22, wherein the composition comprises about 50 to 7500 mg of the compound selected from the group consisting of reduced isoalpha acids, dihydro-isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.
24. (PREVIOUSLY AMENDED) The method of claim 17, wherein the composition comprises about 0.001 to 10 weight percent of the compound selected from the group consisting of reduced isoalpha acids, dihydro-isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.
25. (PREVIOUSLY AMENDED) The method of claim 24, wherein the composition comprises about 0.1 to 1 weight percent of the compound selected from the group consisting of reduced isoalpha acids, dihydro-isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids.

26. (ORIGINAL) The method of claim 17, wherein the nonsteroidal anti-inflammatory compound is selected from the group consisting of salicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetanilide, acetaminophen, phenacetin, mefenamic acid, sodium meclofenamate, tolmetin, ketorolac, diclofenac, ibuprofen, naproxen, sodium daproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, meloxicam, tenoxicam, ampiroxicam, droxicam, piroxicam, phenylbutazone, oxyphenbutazone, anitpyrine, aminopyrine, dipyrone, celecoxib, rofecoxib, nabumetone, apazone, nimensulide, indomethacin, sulindac, and etodolac.
27. (ORIGINAL) The method of claim 26, wherein the nonsteroidal anti-inflammatory is selected from the group consisting of salicylic acid, methyl salicylate, ibuprofen, naproxen, sodium daproxen, fenoprofen, ketoprofen, flurbiprofen, and oxaprozin.
28. (ORIGINAL) The method of claim 17, wherein the composition further comprises a pharmaceutically acceptable carrier.
29. (ORIGINAL) The method of claim 17, wherein the composition is formulated for administration orally, topically, parenterally, or rectally.
30. (PREVIOUSLY AMENDED) The method of claim 17, wherein the compound selected from the group consisting of reduced isoalpha acids, dihydro-isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids is administered concomitantly with said non-steroidal anti-inflammatory compound.
31. (PREVIOUSLY AMENDED) The method of claim 17, wherein said compound selected from the group consisting of reduced isoalpha acids, dihydro-isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids is administered after the administration of said non-steroidal anti-inflammatory compound.
32. (PREVIOUSLY AMENDED) The method of claim 17, wherein said compound selected from the group consisting of reduced isoalpha acids, dihydro-isoalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids is administered before the administration of said non-steroidal anti-inflammatory compound.

33. (PREVIOUSLY AMENDED) The method of reducing gastric toxicity associated with a non-steroidal anti inflammatory compound, comprising administering a compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids to an individual being treated with a non-steroidal anti-inflammatory compound.
34. (PREVIOUSLY AMENDED) A method of reducing gastroenteropathy, comprising administering a compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids to an individual exhibiting a sign or symptom associated with gastroenteropathy
35. (ORIGINAL) The method of claim 34, wherein said gastroenteropathy involves ulceration.
36. (ORIGINAL) The method of claim 35, wherein said ulceration is induced food, an herb, bacteria, fungi or a drug.
37. (PREVIOUSLY PRESENTED) A composition according to claim 1, wherein the compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids is derived from hops.
38. (PREVIOUSLY PRESENTED) The composition of claim 15, wherein reduced isoalpa acid is derived from hops.
39. (PREVIOUSLY PRESENTED) The method of claim 17, wherein the compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids is derived from hops.
40. (PREVIOUSLY PRESENTED) The method of claim 33, wherein the compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids is derived from hops.
41. (PREVIOUSLY PRESENTED) The method of claim 34, wherein the compound selected from the group consisting of reduced isoalpa acids, dihydro-isoalpa acids, tetra-hydroisoalpa acids, and hexa-hydroisoalpa acids is derived from hops.